IKI.E. Karpov

I.E. Karpov

*This is an algorithmically generated author record based on publicly available information.

I.E. Karpov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • L-Arginine as a New Tool in the Intensive Care of Cardiovascular Disorders: Review

    by I.S. Simutis, N.YU. Semigolovskii, I.G. Lobachenko, A.A. Sapegin, M.S. Danilov, E.S. Iusupov, T.N. Enkina, K. Blitsyn, I.E. Karpov, I.V. Suvorova

    Relevance. Cardiovascular diseases (CVDs) remain one of the leading causes of mortality worldwide. In recent years, significant attention has been given to L-arginine, a conditionally essential amino acid that serves as a key precursor of nitric oxide, a critically important mediator of vascular function. Dysregulation of L-arginine metabolism and the development of endothelial dysfunction play a significant pathogenetic role in the development and progression of CVDs. Objective. This review aims to systematize current data on the role of L-arginine in the regulation of vascular tone, its impact on endothelium-dependent vasodilation, and to assess the potential application of L-arginine in the intensive care of cardiovascular diseases. Material and methods. A comprehensive analysis of the results of in vitro and in vivo experimental studies, as well as clinical trials focused on examining the influence of L-arginine on endothelial function, hemodynamic parameters, coronary blood flow, and other cardiovascular system parameters was conducted. Particular attention was given to analyzing the molecular mechanisms of NO-mediated action of L-arginine and its interaction with the arginase enzyme. Results. L-arginine contributes to enhancing endothelium-dependent vasodilation, reducing blood pressure, and can have a positive impact in cases of coronary heart disease, heart failure, and atherosclerosis. It is important to note that the effectiveness of L-arginine therapy can be modulated by the level of ADMA, an endogenous inhibitor of nitric oxide synthase (NOS). Conclusion. L-arginine represents a promising therapeutic agent for use in the intensive care of CVDs, especially in patients facing potential ischemia-reperfusion syndrome. To determine optimal therapeutic strategies, including dosage selection and identification of target patient groups, further large-scale, placebo-controlled clinical studies are necessary.